Showing 141 - 160 results of 449 for search '"clinical trials"', query time: 0.08s Refine Results
  1. 141

    Prediction of hemolytic peptides and their hemolytic concentration by Anand Singh Rathore, Nishant Kumar, Shubham Choudhury, Naman Kumar Mehta, Gajendra P. S. Raghava

    Published 2025-02-01
    “…Abstract Peptide-based drugs often fail in clinical trials due to their toxicity or hemolytic activity against red blood cells (RBCs). …”
    Get full text
    Article
  2. 142

    Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection. by Bryce M Warner, Robert Vendramelli, Amrit S Boese, Jonathan Audet, Nikesh Tailor, Courtney Meilleur, Nathan Glowach, Marnie Willman, Thang Truong, Estella Moffat, Kevin Tierney, Beata Kosak, Irfan Dhanidina, Jarret Engstrom, Bozena Korczak, Ian McGowan, Carissa Embury-Hyatt, Darwyn Kobasa

    Published 2025-01-01
    “…Since the emergence of SARS-CoV-2 and the COVID-19 pandemic, a wide range of treatment options have been evaluated in preclinical studies and clinical trials, with several being approved for use in humans. …”
    Get full text
    Article
  3. 143

    Error fields: personalized robotic movement training that augments one’s more likely mistakes by Naveed Reza Aghamohammadi, Moria Fisher Bittmann, Verena Klamroth-Marganska, Robert Riener, Felix C. Huang, James L. Patton

    Published 2025-02-01
    “…This study reports results from a clinical trial registered on ClinicalTrials.gov with ID: NCT02720341.…”
    Get full text
    Article
  4. 144

    Prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage by Kyle McGrath, Grace Hey, Ghaidaa Ebrahim, Noah Gilberstadt, David Mahan, Brandon Lucke-Wold

    Published 2023-12-01
    “…Numerous preclinical investigations highlight novel targets related to the immune response that could prove effective at improving outcomes in clinical trials. Further investigation of the glymphatic system and its role in PHCV pathogenesis could result in novel pharmacologic targets. …”
    Get full text
    Article
  5. 145

    Rimegepant for the treatment of migraine by Amnon A. Berger, Ariel Winnick, Austin H. Carroll, Alexandra Welschmeyer, Nathan Li, Marc Colon, Antonella Paladini, Giovanni F. Ramírez, Jamal Hasoon, Elyse M. Cornett, Jaehong Song, Giustino Varrassi, Adam M. Kaye, Alan D. Kaye, Latha Ganti

    Published 2022-10-01
    “…Rimegepant, a second-generation gepant, has shown efficacy in several clinical trials in treating acute migraine. Ongoing trials are also evaluating its role in migraine prophylaxis, and results are promising. …”
    Get full text
    Article
  6. 146

    Promising Neuroprotective Effects of Dracocephalum Species: Mechanistic Perspectives by Marjan Talebi, Alireza Ghassempour, Afsoon Feizi, Seyed Abdulmajid Ayatollahi, Mehrdad Faizi

    Published 2024-12-01
    “…These findings suggest that Dracocephalum spp. and their phytochemicals have neuroprotective effects by targeting the regulation of various pathways. Therefore, clinical trials should be performed to confirm the in vitro and animal findings. …”
    Get full text
    Article
  7. 147

    Gastric Cytoprotection as Basis of Gastrointestinal Mucosa Protection and Repair in Erosive Ulcerative Lesions of Various Aetiologies by K. V. Ivashkin, E. A. Izatullaev, V. R. Korneeva

    Published 2020-12-01
    “…In experiment, MMSC prevented the ethanol-induced GM damage, stimulated mucin release and its redistribution on the GM surface; in clinical trials, MMSC effectively facilitated remission in duodenal ulcer.Conclusion. …”
    Get full text
    Article
  8. 148

    Nutraceuticals and Pharmaceuticals by E. A. Poluektova, A. G. Beniashvili, R. V. Maslennikov

    Published 2020-05-01
    “…Some nutraceuticals, such as probiotics, have confirmed their effectiveness in clinical trials, while the beneficial properties of others require further elucidation.Conclusions. …”
    Get full text
    Article
  9. 149

    Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases by Leilei Chen, Qingqing Shen, Yingjuan Liu, Yunqi Zhang, Liping Sun, Xizhen Ma, Ning Song, Junxia Xie

    Published 2025-02-01
    “…Additionally, the promising results and limitations observed in clinical trials of these metal ion chelators will also be addressed. …”
    Get full text
    Article
  10. 150

    Phytocannabinoids: a new frontier in Alzheimer’s disease management by Jagadeesh S. Rao

    Published 2024-09-01
    “…At present, numerous FDA-controlled clinical trials are being conducted to assess the beneficial impacts of THC and CBD in the treatment of cognitive and neuropsychiatric symptoms associated with AD. …”
    Get full text
    Article
  11. 151
  12. 152

    Assessment of Bowel Preparation Using Low-Volume Sulphate-Based Preparations in Comparison with Macrogols: A Multicenter, Randomized, Comparative Clinical Study of the 3rd Phase by E. D. Fedorov, V. V. Veselov, S. V. Kashin, E. V. Tikhomirova, A. V. Veselov, D. V. Zavyalov, A. Kornowski, T. E. Gorskaya, M. Volteau, T. Ponchon

    Published 2019-05-01
    “…This study is registered with the ClinicalTrials.gov Registry of Clinical Trials, No. NCT02321462.Conflict of interest: this study was sponsored by Ipsen Pharma.Acknowledgements: the authors express their sincere gratitude to all the patients who participated in the study, as well as to specialists having provided medical care for the patients, researchers and employees of the participant research centres. …”
    Get full text
    Article
  13. 153

    Role of nutritional factors at the irritable bowel syndrome by Yu. O. Shulpekova, A. V. Sedova

    Published 2015-10-01
    “…Efficacy of functional food products containing bacteria of probiotic strain Bifidobacterium animalis sp. lactis DN-173 010 for treatment of IBS symptoms is demonstrated in clinical trials. At detection of symptoms link to intake of specific products it is necessary to exclude food allergy and enzymopathies (e.g. lactase deficiency), which should be defined as independent diseases under the «mask» of irritable bowel syndrome.Conclusion. …”
    Get full text
    Article
  14. 154

    Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment by Rahul Navab, Pragyat Futela, Verkha Kumari, Jayesh Valecha, Ramansh Bandhu Gupta, Rohit Jain

    Published 2025-01-01
    “…These therapies exhibit impressive efficacy in clinical trials, leading to FDA approvals for specific MM patient populations. …”
    Get full text
    Article
  15. 155
  16. 156

    Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles by Delaram Doroud, Mojtaba Daneshi, Fatemeh Kazemi-Lomedash, Zohre Eftekhari

    Published 2025-02-01
    “…This guidance is essential for researchers and manufacturers to design effective vaccines that can progress to clinical trials safely. …”
    Get full text
    Article
  17. 157

    Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer by E. V. Ledin, A. V. Kochatkov

    Published 2018-08-01
    “…The meta-analysis (2015) of 4 randomized third-phase clinical trials (EORTC 22921, I-CNR-RT, PROCTORSCRIPT, CHRONICLE) demonstrated the lack of significant of 5-fluorouracil-based adjuvant chemotherapy. …”
    Get full text
    Article
  18. 158

    Meta-Analysis and Systematic Review of the Role of Appendectomy in the Pathogenesis of Colorectal Cancer by M.I. A. Nezhad, N. P. Yabandeh

    Published 2024-05-01
    “…Our systematic investigation utilized sources including the Cochrane Library, Embase, PubMed, ClinicalTrials.gov, and Web of Science, covering research up to February 1, 2023. …”
    Get full text
    Article
  19. 159

    Electronic Cigarettes: Ally or an Enemy in Combating Tobacco-Use-Associated Diseases - An Integrative Review by Hunny Sharma, Manisha Ruikar

    Published 2023-04-01
    “…Methods: This integrative review includes findings from Randomized and non-randomized clinical trials, and laboratory-based Human studies; published in the English language in the last four years. …”
    Get full text
    Article
  20. 160

    Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer by Jing Zhang, Wenjie Li

    Published 2025-02-01
    “…Abstract Background While clinical trials have demonstrated enduring responses to amivantamab among advanced non-small cell lung cancer (NSCLC) patients bearing EGFR exon 20 insertion mutations, the associated toxicity profile in real-world scenarios remains elusive. …”
    Get full text
    Article